Defusing SARS-CoV-2: Emergency Brakes in a Vaccine Failure Scenario
| Autor: | Ariel Fernández |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Cell entry
Pharmacology 2019-20 coronavirus outbreak CIENCIAS MÉDICAS Y DE LA SALUD Coronavirus disease 2019 (COVID-19) SARS-CoV-2 business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Biotecnología relacionada con la Salud Evolutionary change COVID-19 Virology Biotecnología de la Salud antibody Selective advantage Medicine purl.org/becyt/ford/3 [https] Pharmacology (medical) purl.org/becyt/ford/3.4 [https] business Vaccine failure virus transmissibility |
| Zdroj: | ACS Pharmacology & Translational Science ACS Pharmacol Transl Sci CONICET Digital (CONICET) Consejo Nacional de Investigaciones Científicas y Técnicas instacron:CONICET |
| ISSN: | 2575-9108 |
| DOI: | 10.1021/acsptsci.0c00152 |
| Popis: | Deactivation of primed SARS-CoV-2 prior to cell entry constitutes an emergency brake in COVID-19 infection if vaccine-induced antibodies fail to block recognition of the human angiotensin-converting enzyme 2 (hACE2) receptor. The timing and locus for the therapeutic intervention are dictated by the cell entry mechanism and by the selective advantage of the dominant D614G mutation. Fil: Fernandez, Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur; Argentina |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|